CN102262097A - 一种系统性红斑狼疮图谱模型的构建方法及其图谱模型 - Google Patents
一种系统性红斑狼疮图谱模型的构建方法及其图谱模型 Download PDFInfo
- Publication number
- CN102262097A CN102262097A CN2011101074297A CN201110107429A CN102262097A CN 102262097 A CN102262097 A CN 102262097A CN 2011101074297 A CN2011101074297 A CN 2011101074297A CN 201110107429 A CN201110107429 A CN 201110107429A CN 102262097 A CN102262097 A CN 102262097A
- Authority
- CN
- China
- Prior art keywords
- model
- spectrogram
- sle
- construction method
- steps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000010276 construction Methods 0.000 title claims abstract description 31
- 201000000596 systemic lupus erythematosus Diseases 0.000 title abstract description 10
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims abstract description 28
- 239000006228 supernatant Substances 0.000 claims abstract description 27
- 238000005481 NMR spectroscopy Methods 0.000 claims abstract description 23
- 239000007788 liquid Substances 0.000 claims abstract description 23
- 238000004458 analytical method Methods 0.000 claims abstract description 19
- 238000007619 statistical method Methods 0.000 claims abstract description 19
- 238000000513 principal component analysis Methods 0.000 claims abstract description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000001257 hydrogen Substances 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 13
- 241000282414 Homo sapiens Species 0.000 claims abstract description 10
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- 239000008280 blood Substances 0.000 claims abstract description 8
- 238000012545 processing Methods 0.000 claims abstract description 8
- 238000010257 thawing Methods 0.000 claims abstract description 7
- 238000012937 correction Methods 0.000 claims abstract description 6
- 238000001228 spectrum Methods 0.000 claims description 36
- 230000009885 systemic effect Effects 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 19
- 230000008859 change Effects 0.000 claims description 9
- 238000002790 cross-validation Methods 0.000 claims description 8
- 238000010348 incorporation Methods 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 230000010354 integration Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000002474 experimental method Methods 0.000 claims description 5
- 230000002902 bimodal effect Effects 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 230000005311 nuclear magnetism Effects 0.000 claims description 4
- 238000000079 presaturation Methods 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 239000012530 fluid Substances 0.000 abstract 4
- 238000004611 spectroscopical analysis Methods 0.000 abstract 2
- 238000005119 centrifugation Methods 0.000 abstract 1
- 230000008014 freezing Effects 0.000 abstract 1
- 238000007710 freezing Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 11
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000003909 pattern recognition Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035762 Disorder of lipid metabolism Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- -1 Ileu) Chemical compound 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000003087 glucogenic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010239 partial least squares discriminant analysis Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110107429.7A CN102262097B (zh) | 2011-04-27 | 2011-04-27 | 一种系统性红斑狼疮图谱模型的构建方法及其图谱模型 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110107429.7A CN102262097B (zh) | 2011-04-27 | 2011-04-27 | 一种系统性红斑狼疮图谱模型的构建方法及其图谱模型 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102262097A true CN102262097A (zh) | 2011-11-30 |
CN102262097B CN102262097B (zh) | 2014-07-02 |
Family
ID=45008806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110107429.7A Active CN102262097B (zh) | 2011-04-27 | 2011-04-27 | 一种系统性红斑狼疮图谱模型的构建方法及其图谱模型 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102262097B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105486799A (zh) * | 2016-01-25 | 2016-04-13 | 中国药科大学 | 用于诊断急性冠脉综合征的代谢标志物 |
CN113933434A (zh) * | 2021-10-26 | 2022-01-14 | 深圳临研医学有限公司 | 系统性红斑狼疮的代谢标志物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6232522B1 (en) * | 1990-01-31 | 2001-05-15 | Oklahoma Medical Research Foundation | Non-human animal model for systemic lupus erythematosis |
CN101329302A (zh) * | 2008-07-23 | 2008-12-24 | 戴勇 | 用于系统性红斑狼疮诊断的蛋白质指纹图谱模型 |
CN101916325A (zh) * | 2010-06-30 | 2010-12-15 | 戴勇 | 系统性红斑狼疮阶段性蛋白表达差异图谱模型及构建方法 |
-
2011
- 2011-04-27 CN CN201110107429.7A patent/CN102262097B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6232522B1 (en) * | 1990-01-31 | 2001-05-15 | Oklahoma Medical Research Foundation | Non-human animal model for systemic lupus erythematosis |
CN101329302A (zh) * | 2008-07-23 | 2008-12-24 | 戴勇 | 用于系统性红斑狼疮诊断的蛋白质指纹图谱模型 |
CN101916325A (zh) * | 2010-06-30 | 2010-12-15 | 戴勇 | 系统性红斑狼疮阶段性蛋白表达差异图谱模型及构建方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105486799A (zh) * | 2016-01-25 | 2016-04-13 | 中国药科大学 | 用于诊断急性冠脉综合征的代谢标志物 |
CN105486799B (zh) * | 2016-01-25 | 2017-12-01 | 中国药科大学 | 用于诊断急性冠脉综合征的代谢标志物 |
CN113933434A (zh) * | 2021-10-26 | 2022-01-14 | 深圳临研医学有限公司 | 系统性红斑狼疮的代谢标志物 |
CN113933434B (zh) * | 2021-10-26 | 2023-12-12 | 深圳临研医学有限公司 | 系统性红斑狼疮的代谢标志物 |
Also Published As
Publication number | Publication date |
---|---|
CN102262097B (zh) | 2014-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bales et al. | Use of high-resolution proton nuclear magnetic resonance spectroscopy for rapid multi-component analysis of urine. | |
Tate et al. | Distinction between normal and renal cell carcinoma kidney cortical biopsy samples using pattern recognition of 1H magic angle spinning (MAS) NMR spectra | |
Andronesi et al. | Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy | |
Saude et al. | Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy | |
JP4829496B2 (ja) | 代謝表現型 | |
Senn et al. | Translating metabolomics to cardiovascular biomarkers | |
US6617167B2 (en) | Method of determining presence and concentration of lipoprotein X in blood plasma and serum | |
US20110238319A1 (en) | method of diagnosing a respiratory disease | |
Haslauer et al. | Guidelines for the use of deuterium oxide (D2O) in 1H NMR metabolomics | |
Hochrein et al. | Data normalization of 1H NMR metabolite fingerprinting data sets in the presence of unbalanced metabolite regulation | |
CN102305802B (zh) | Hbv感染性与酒精性肝硬化差异表达图谱模型及其构建方法 | |
Shao et al. | Characterization of ankylosing spondylitis and rheumatoid arthritis using 1 H NMR-based metabolomics of human fecal extracts | |
Wallmeier et al. | Quantification of Metabolites by NMR Spectroscopy in the Presence of Protein | |
Louis et al. | Phenotyping human blood plasma by 1 H-NMR: a robust protocol based on metabolite spiking and its evaluation in breast cancer | |
CN102262098B (zh) | 类风湿关节炎图谱模型的构建方法及其图谱模型 | |
AU2016320637A1 (en) | System and method for detecting and monitoring Post Traumatic Stress Disorder (PTSD) using magnetic resonance spectroscopy (MRS) | |
CN102262097B (zh) | 一种系统性红斑狼疮图谱模型的构建方法及其图谱模型 | |
CN106153739A (zh) | 一种基于代谢组学技术诊断肝癌的模型 | |
Li et al. | Metabonomics analysis of the urine of rats with Qi deficiency and blood stasis syndrome based on NMR techniques | |
EP2812690B1 (en) | Diagnosing multiple sclerosis | |
CN104615903B (zh) | 一种模型自适应的nmr代谢组学数据归一化方法 | |
Cicero et al. | A small sided game session affects salivary metabolite levels in young soccer players | |
CN103430022A (zh) | 诊断方法 | |
CN115389771A (zh) | 一种用于难治性抑郁症诊断的标志物及其应用 | |
CN107576747A (zh) | 癸酸和前列腺素e2组合作为巨大儿辅助诊断标志物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Dai Yong Inventor after: OuYang Xin Inventor after: Wang Qingwen Inventor after: Tang Donge Inventor before: Dai Yong Inventor before: OuYang Xin |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230814 Address after: Room 201, Building 10, Taizhou Cross border E-commerce Industrial Park, No. 638 Donghuan Avenue, Haihong Street, Taizhou Bay New Area, Zhejiang Province, 318000 (self declared) Patentee after: Taizhou Linyan Medical Technology Co.,Ltd. Address before: 518100 Shenzhen People's Hospital, Guangdong Province Patentee before: Dai Yong Patentee before: OuYang Xin |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231113 Address after: 232000 Tian Jia An District, Huainan City, Anhui Patentee after: Anhui University of Science and Technology Address before: Room 201, Building 10, Taizhou Cross border E-commerce Industrial Park, No. 638 Donghuan Avenue, Haihong Street, Taizhou Bay New Area, Zhejiang Province, 318000 (self declared) Patentee before: Taizhou Linyan Medical Technology Co.,Ltd. |